Biological
mRNA-1273.214 COVID-19 vaccine clinical trials
- studies test it
- 9
- open now
- 0
- in phase 3
- 6
- first study started
- 2021
How studies write it
Studies that test it under each name
Name
Studies by the year they started
9 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 2
ModernaTX, Inc. (7) · Murdoch Childrens Research Institute (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
mRNA-1345 respiratory syncytial virus vaccine (2) · 2019-nCoV Vaccine mRNA-1273 (2) · Elasomeran/Davesomeran (1) · mRNA-1010 influenza vaccine (1) · MRNA-1045 (1) · MRNA-1230 (1)
Studies
Open first, then newest update. How each study uses mRNA-1273.214 COVID-19 vaccine is read from its arms, and is right about nine times in ten.
Testing it · 9
- COVID-19 Booster Study in Healthy Adults in AustraliaActive, not recruitingPhase 3Murdoch Childrens Research InstituteNCT05658523Written as Bivalent Moderna
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05330975Written as mRNA-1273.214
- A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05436834Written as mRNA-1273.214
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsTerminatedPhase 2ModernaTX, Inc.NCT05584202Written as mRNA-1273.214
- A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCompletedPhase 2/3ModernaTX, Inc.NCT04796896Written as mRNA-1273.214
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedPhase 2/3ModernaTX, Inc.NCT04927065Written as mRNA-1273.214
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19CompletedPhase 2/3ModernaTX, Inc.NCT05249829Written as mRNA-1273.214
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedPhase 1ModernaTX, Inc.NCT05585632Written as mRNA-1273.214
- Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in AdultsCompletedPhase 2Sheba Medical CenterNCT05383560Written as mRNA-1273.214 Vaccine
Codes
What other systems call mRNA-1273.214 COVID-19 vaccine · ClinicalTrials.gg INT001890
- MeSH (NLM) C000722752mRNA-1273.214 COVID-19 vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722752 | mRNA-1273.214 COVID-19 vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.